These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8819224)

  • 21. [Investigation of antinuclear antibodies in chronic hepatitis B patients].
    Şener AG; Aydın N; Ceylan C; Kırdar S
    Mikrobiyol Bul; 2018 Oct; 52(4):425-430. PubMed ID: 30522427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphoblastoid alpha-interferon for chronic hepatitis C: a randomized controlled study.
    Castilla A; Camps-Bansell J; Civeira MP; Prieto J
    Am J Gastroenterol; 1993 Feb; 88(2):233-9. PubMed ID: 8424427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum autoantibodies positivity prevalence in patients with chronic HCV and impact on pegylated interferon and ribavirin treatment response.
    Khairy M; El-Raziky M; El-Akel W; Abdelbary MS; Khatab H; El-Kholy B; Esmat G; Mabrouk M
    Liver Int; 2013 Nov; 33(10):1504-9. PubMed ID: 23763380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon treatment for hepatitis C virus infection in patients on haemodialysis.
    Chan TM; Wu PC; Lau JY; Lok AS; Lai CL; Cheng IK
    Nephrol Dial Transplant; 1997 Jul; 12(7):1414-9. PubMed ID: 9249778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of chronic hepatitis C infection with interferon alpha-2a in a Turkish population.
    Simsek H; Tatar G; Savas C; Telatar H
    J Int Med Res; 1996; 24(1):132-7. PubMed ID: 8674791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of interferon combined glycyrrhizin therapy in patients with chronic hepatitis C resistant to interferon therapy].
    Okuno T; Arai K; Shindo M
    Nihon Rinsho; 1994 Jul; 52(7):1823-7. PubMed ID: 8078202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term prognosis of chronic hepatitis C after treatment with interferon alpha 2b and characterization of incomplete responders.
    Hakozaki Y; Shirahama T; Katou M; Nakagawa K; Oba K; Yoshii O; Matsumoto T; Kuwabara N; Mitamura K
    Am J Gastroenterol; 1996 Oct; 91(10):2144-9. PubMed ID: 8855738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C.
    Chen CH; Lee CM; Chen CH; Hu TH; Wang JH; Hung CH; Chung CH; Lu SN
    Chang Gung Med J; 2010; 33(3):258-65. PubMed ID: 20584503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological effects following administration of interferon-alpha in patients with chronic hepatitis C virus (cHCV) infection.
    Jirillo E; Greco B; Caradonna L; Satalino R; Amati L; Cozzolongo R; Cuppone R; Manghisi OG
    Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):355-74. PubMed ID: 8872490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection.
    Betterle C; Fabris P; Zanchetta R; Pedini B; Tositti G; Bosi E; de Lalla F
    Diabetes Care; 2000 Aug; 23(8):1177-81. PubMed ID: 10937518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antineutrophil cytoplasmic antibody in patients with antinuclear antibody-positive chronic hepatitis C.
    Ohira H; Tojo J; Shinzawa J; Suzuki T; Miyata M; Nishimaki T; Kasukawa R
    Fukushima J Med Sci; 1998 Dec; 44(2):83-92. PubMed ID: 10091380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C].
    Fernández I; Castellano G; Canga F; Colina F; García H; Fuertes A; Casis B; Martín A; Solís JA
    Gastroenterol Hepatol; 1995 Feb; 18(2):66-72. PubMed ID: 7621277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.
    Hsieh MY; Dai CY; Lee LP; Huang JF; Tsai WC; Hou NJ; Lin ZY; Chen SC; Wang LY; Chang WY; Chuang WL; Yu ML
    J Clin Pathol; 2008 Mar; 61(3):333-7. PubMed ID: 17545561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma.
    Imai H; Nakano Y; Kiyosawa K; Tan EM
    Cancer; 1993 Jan; 71(1):26-35. PubMed ID: 8380118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa.
    Tanaka E; Kiyosawa K; Matsumoto A; Kashiwakuma T; Hasegawa A; Mori H; Yanagihara O; Ohta Y
    Hepatology; 1996 Jun; 23(6):1330-3. PubMed ID: 8675147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C.
    Muratori P; Muratori L; Guidi M; Granito A; Susca M; Lenzi M; Bianchi FB
    Clin Infect Dis; 2005 Feb; 40(4):501-7. PubMed ID: 15712070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does the presence of serum autoantibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C?
    Wada M; Kang KB; Kinugasa A; Shintani S; Sawada K; Nishigami T; Shimoyama T
    Intern Med; 1997 Apr; 36(4):248-54. PubMed ID: 9187562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C.
    Hakozaki Y; Shirahama T; Katou M; Nakagawa K; Oba K; Mitamura K
    Am J Gastroenterol; 1995 Aug; 90(8):1246-9. PubMed ID: 7639224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.
    Rasi G; DiVirgilio D; Mutchnick MG; Colella F; Sinibaldi-Vallebona P; Pierimarchi P; Valli B; Garaci E
    Gut; 1996 Nov; 39(5):679-83. PubMed ID: 9026482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinico-pathological predictive factors of response to interferon therapy in chronic hepatitis C.
    Thavarungkul P; Toriyama K; Kusuda M; Kamito H; Kamito M; Nakayama T; Kato Y; Itakura H
    Southeast Asian J Trop Med Public Health; 1996 Mar; 27(1):85-90. PubMed ID: 9031407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.